CA1266628A - Fabrication et expression de genes structuraux - Google Patents

Fabrication et expression de genes structuraux

Info

Publication number: CA1266628A
Authority: CA; Canada
Prior art keywords: sequence; duplex; dna; bases; gene
Prior art date: 1982-05-06
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

CA000427371A

Other languages

English (en)

Inventor

Yitzhak Stabinsky

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Amgen Inc

Original Assignee

Amgen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1982-05-06

Filing date

1983-05-04

Publication date

1990-03-13

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23481109&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA1266628(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1983-05-04 Application filed by Amgen Inc filed Critical Amgen Inc

1990-03-13 Application granted granted Critical

1990-03-13 Publication of CA1266628A publication Critical patent/CA1266628A/fr

Status Expired - Lifetime legal-status Critical Current

Links

108090000623 proteins and genes Proteins 0.000 title claims abstract description 143
230000014509 gene expression Effects 0.000 title claims abstract description 37
238000004519 manufacturing process Methods 0.000 title abstract description 30
108020004414 DNA Proteins 0.000 claims abstract description 81
102000053602 DNA Human genes 0.000 claims abstract description 78
238000000034 method Methods 0.000 claims abstract description 66
108020004705 Codon Proteins 0.000 claims abstract description 46
102000004169 proteins and genes Human genes 0.000 claims abstract description 40
230000015572 biosynthetic process Effects 0.000 claims abstract description 33
150000001413 amino acids Chemical class 0.000 claims abstract description 31
238000003786 synthesis reaction Methods 0.000 claims abstract description 22
244000005700 microbiome Species 0.000 claims abstract description 15
238000002360 preparation method Methods 0.000 claims abstract description 13
230000000295 complement effect Effects 0.000 claims description 26
239000002773 nucleotide Substances 0.000 claims description 23
125000003729 nucleotide group Chemical group 0.000 claims description 19
239000000203 mixture Substances 0.000 claims description 11
239000011541 reaction mixture Substances 0.000 claims description 8
238000000137 annealing Methods 0.000 claims description 5
241000282414 Homo sapiens Species 0.000 abstract description 22
241000588724 Escherichia coli Species 0.000 abstract description 15
230000004927 fusion Effects 0.000 abstract description 8
238000006257 total synthesis reaction Methods 0.000 abstract description 2
JMHFFDIMOUKDCZ-XKMGUCBZSA-N chembl2369948 Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](CCSC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)C1=CC=CC=C1 JMHFFDIMOUKDCZ-XKMGUCBZSA-N 0.000 abstract 2
235000018102 proteins Nutrition 0.000 description 32
102000004196 processed proteins & peptides Human genes 0.000 description 29
108090000765 processed proteins & peptides Proteins 0.000 description 29
235000001014 amino acid Nutrition 0.000 description 28
229940024606 amino acid Drugs 0.000 description 28
210000004027 cell Anatomy 0.000 description 28
229920001184 polypeptide Polymers 0.000 description 26
239000000047 product Substances 0.000 description 23
239000013598 vector Substances 0.000 description 23
108091028043 Nucleic acid sequence Proteins 0.000 description 17
239000013612 plasmid Substances 0.000 description 17
238000006243 chemical reaction Methods 0.000 description 15
230000009466 transformation Effects 0.000 description 15
238000005755 formation reaction Methods 0.000 description 12
239000012634 fragment Substances 0.000 description 11
108020004999 messenger RNA Proteins 0.000 description 11
108020004511 Recombinant DNA Proteins 0.000 description 10
238000007792 addition Methods 0.000 description 10
238000005304 joining Methods 0.000 description 10
239000000243 solution Substances 0.000 description 10
102100038796 E3 ubiquitin-protein ligase TRIM13 Human genes 0.000 description 8
101000664589 Homo sapiens E3 ubiquitin-protein ligase TRIM13 Proteins 0.000 description 8
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 8
241000699666 Mus <mouse, genus> Species 0.000 description 8
125000003275 alpha amino acid group Chemical group 0.000 description 8
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 8
230000002255 enzymatic effect Effects 0.000 description 8
239000000499 gel Substances 0.000 description 8
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 8
239000000126 substance Substances 0.000 description 8
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 8
238000001962 electrophoresis Methods 0.000 description 7
238000003780 insertion Methods 0.000 description 7
230000037431 insertion Effects 0.000 description 7
238000002955 isolation Methods 0.000 description 7
238000011160 research Methods 0.000 description 7
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 6
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 6
108090000790 Enzymes Proteins 0.000 description 6
239000007995 HEPES buffer Substances 0.000 description 6
239000000872 buffer Substances 0.000 description 6
108020001507 fusion proteins Proteins 0.000 description 6
102000037865 fusion proteins Human genes 0.000 description 6
102000012410 DNA Ligases Human genes 0.000 description 5
108010061982 DNA Ligases Proteins 0.000 description 5
102000004190 Enzymes Human genes 0.000 description 5
229930182817 methionine Natural products 0.000 description 5
102000039446 nucleic acids Human genes 0.000 description 5
108020004707 nucleic acids Proteins 0.000 description 5
150000007523 nucleic acids Chemical class 0.000 description 5
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
230000008569 process Effects 0.000 description 5
238000013518 transcription Methods 0.000 description 5
230000035897 transcription Effects 0.000 description 5
238000013519 translation Methods 0.000 description 5
229930024421 Adenine Natural products 0.000 description 4
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 4
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 4
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
229910019142 PO4 Inorganic materials 0.000 description 4
229920005654 Sephadex Polymers 0.000 description 4
239000012507 Sephadex™ Substances 0.000 description 4
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
241000700605 Viruses Species 0.000 description 4
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
229960000643 adenine Drugs 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
230000008901 benefit Effects 0.000 description 4
238000003776 cleavage reaction Methods 0.000 description 4
229940104302 cytosine Drugs 0.000 description 4
230000002068 genetic effect Effects 0.000 description 4
OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 4
239000010452 phosphate Substances 0.000 description 4
229920002401 polyacrylamide Polymers 0.000 description 4
238000000746 purification Methods 0.000 description 4
230000007017 scission Effects 0.000 description 4
229940113082 thymine Drugs 0.000 description 4
230000003612 virological effect Effects 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
108091034117 Oligonucleotide Proteins 0.000 description 3
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
230000027455 binding Effects 0.000 description 3
238000009835 boiling Methods 0.000 description 3
238000010367 cloning Methods 0.000 description 3
230000000875 corresponding effect Effects 0.000 description 3
238000010348 incorporation Methods 0.000 description 3
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 3
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
235000021317 phosphate Nutrition 0.000 description 3
229920000642 polymer Polymers 0.000 description 3
239000002157 polynucleotide Substances 0.000 description 3
108091008146 restriction endonucleases Proteins 0.000 description 3
229920002477 rna polymer Polymers 0.000 description 3
RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
VNDYJBBGRKZCSX-UHFFFAOYSA-L zinc bromide Chemical compound Br[Zn]Br VNDYJBBGRKZCSX-UHFFFAOYSA-L 0.000 description 3
-1 2-nitrophenylsulfenyl Chemical class 0.000 description 2
KIUYPHAMDKDICO-WHFBIAKZSA-N Ala-Asp-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O KIUYPHAMDKDICO-WHFBIAKZSA-N 0.000 description 2
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
108020004638 Circular DNA Proteins 0.000 description 2
102100031780 Endonuclease Human genes 0.000 description 2
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
101000976075 Homo sapiens Insulin Proteins 0.000 description 2
SAEWJTCJQVZQNZ-IUKAMOBKSA-N Ile-Thr-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)N SAEWJTCJQVZQNZ-IUKAMOBKSA-N 0.000 description 2
108090001061 Insulin Proteins 0.000 description 2
108010047761 Interferon-alpha Proteins 0.000 description 2
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
XWEVVRRSIOBJOO-SRVKXCTJSA-N Leu-Pro-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(O)=O XWEVVRRSIOBJOO-SRVKXCTJSA-N 0.000 description 2
MUCIDQMDOYQYBR-IHRRRGAJSA-N Leu-Pro-His Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)N MUCIDQMDOYQYBR-IHRRRGAJSA-N 0.000 description 2
XGDCYUQSFDQISZ-BQBZGAKWSA-N Leu-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(O)=O XGDCYUQSFDQISZ-BQBZGAKWSA-N 0.000 description 2
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
108091005804 Peptidases Proteins 0.000 description 2
XNMYNGDKJNOKHH-BZSNNMDCSA-N Phe-Ser-Tyr Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O XNMYNGDKJNOKHH-BZSNNMDCSA-N 0.000 description 2
108091000080 Phosphotransferase Proteins 0.000 description 2
239000004365 Protease Substances 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
108010056088 Somatostatin Proteins 0.000 description 2
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
125000000539 amino acid group Chemical group 0.000 description 2
239000000908 ammonium hydroxide Substances 0.000 description 2
230000003321 amplification Effects 0.000 description 2
230000000202 analgesic effect Effects 0.000 description 2
239000004202 carbamide Substances 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000009833 condensation Methods 0.000 description 2
230000005494 condensation Effects 0.000 description 2
239000000470 constituent Substances 0.000 description 2
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 2
239000011521 glass Substances 0.000 description 2
230000001965 increasing effect Effects 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
239000013067 intermediate product Substances 0.000 description 2
239000003550 marker Substances 0.000 description 2
239000000463 material Substances 0.000 description 2
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
238000003199 nucleic acid amplification method Methods 0.000 description 2
239000002777 nucleoside Substances 0.000 description 2
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
102000020233 phosphotransferase Human genes 0.000 description 2
238000011084 recovery Methods 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
238000012163 sequencing technique Methods 0.000 description 2
239000000741 silica gel Substances 0.000 description 2
229910002027 silica gel Inorganic materials 0.000 description 2
239000007858 starting material Substances 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
238000012795 verification Methods 0.000 description 2
210000005253 yeast cell Anatomy 0.000 description 2
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical group OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
AYKYXWQEBUNJCN-UHFFFAOYSA-N 3-methylfuran-2,5-dione Chemical compound CC1=CC(=O)OC1=O AYKYXWQEBUNJCN-UHFFFAOYSA-N 0.000 description 1
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
PAIHPOGPJVUFJY-WDSKDSINSA-N Ala-Glu-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O PAIHPOGPJVUFJY-WDSKDSINSA-N 0.000 description 1
USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
239000005695 Ammonium acetate Substances 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
241000271566 Aves Species 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
108091032955 Bacterial small RNA Proteins 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
241000283707 Capra Species 0.000 description 1
108700010070 Codon Usage Proteins 0.000 description 1
108010042407 Endonucleases Proteins 0.000 description 1
102000009025 Endorphins Human genes 0.000 description 1
108010049140 Endorphins Proteins 0.000 description 1
108091029865 Exogenous DNA Proteins 0.000 description 1
108700039691 Genetic Promoter Regions Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
101000632994 Homo sapiens Somatostatin Proteins 0.000 description 1
102000002265 Human Growth Hormone Human genes 0.000 description 1
108010000521 Human Growth Hormone Proteins 0.000 description 1
239000000854 Human Growth Hormone Substances 0.000 description 1
ZMJBYMUCKBYSCP-UHFFFAOYSA-N Hydroxycitric acid Chemical compound OC(=O)C(O)C(O)(C(O)=O)CC(O)=O ZMJBYMUCKBYSCP-UHFFFAOYSA-N 0.000 description 1
QGXQHJQPAPMACW-PPCPHDFISA-N Ile-Thr-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)O)N QGXQHJQPAPMACW-PPCPHDFISA-N 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
102000006992 Interferon-alpha Human genes 0.000 description 1
108091092195 Intron Proteins 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
102000003960 Ligases Human genes 0.000 description 1
108090000364 Ligases Proteins 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
241000283956 Manis Species 0.000 description 1
IHRFZLQEQVHXFA-RHYQMDGZSA-N Met-Thr-Lys Chemical compound CSCC[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCCCN IHRFZLQEQVHXFA-RHYQMDGZSA-N 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
101500024096 Mus musculus Corticotropin Proteins 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
241001467460 Myxogastria Species 0.000 description 1
101100205189 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) leu-5 gene Proteins 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
108010076181 Proinsulin Proteins 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
101150039863 Rich gene Proteins 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
102000005157 Somatostatin Human genes 0.000 description 1
108700005078 Synthetic Genes Proteins 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
YFOCMOVJBQDBCE-NRPADANISA-N Val-Ala-Glu Chemical compound C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](C(C)C)N YFOCMOVJBQDBCE-NRPADANISA-N 0.000 description 1
108020005202 Viral DNA Proteins 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
230000004075 alteration Effects 0.000 description 1
XQJHRCVXRAJIDY-UHFFFAOYSA-N aminophosphine Chemical compound PN XQJHRCVXRAJIDY-UHFFFAOYSA-N 0.000 description 1
235000019257 ammonium acetate Nutrition 0.000 description 1
229940043376 ammonium acetate Drugs 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000000712 assembly Effects 0.000 description 1
238000000429 assembly Methods 0.000 description 1
230000003190 augmentative effect Effects 0.000 description 1
239000011324 bead Substances 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
208000037516 chromosome inversion disease Diseases 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000013058 crude material Substances 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000006642 detritylation reaction Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
230000029087 digestion Effects 0.000 description 1
230000000694 effects Effects 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
239000012467 final product Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
101150016518 for gene Proteins 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
238000010359 gene isolation Methods 0.000 description 1
238000007429 general method Methods 0.000 description 1
230000008570 general process Effects 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
102000045305 human SST Human genes 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
AFQIYTIJXGTIEY-UHFFFAOYSA-N hydrogen carbonate;triethylazanium Chemical compound OC(O)=O.CCN(CC)CC AFQIYTIJXGTIEY-UHFFFAOYSA-N 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
229960000310 isoleucine Drugs 0.000 description 1
238000002372 labelling Methods 0.000 description 1
238000011031 large-scale manufacturing process Methods 0.000 description 1
239000007788 liquid Substances 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
150000002739 metals Chemical class 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
230000002906 microbiologic effect Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
239000000178 monomer Substances 0.000 description 1
239000013642 negative control Substances 0.000 description 1
LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 1
150000003833 nucleoside derivatives Chemical class 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
239000002245 particle Substances 0.000 description 1
239000008188 pellet Substances 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
230000001817 pituitary effect Effects 0.000 description 1
239000013600 plasmid vector Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
102000040430 polynucleotide Human genes 0.000 description 1
108091033319 polynucleotide Proteins 0.000 description 1
230000003334 potential effect Effects 0.000 description 1
230000000063 preceeding effect Effects 0.000 description 1
239000002243 precursor Substances 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
238000003127 radioimmunoassay Methods 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
230000010076 replication Effects 0.000 description 1
238000010839 reverse transcription Methods 0.000 description 1
125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
229960000553 somatostatin Drugs 0.000 description 1
239000000758 substrate Substances 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
230000009897 systematic effect Effects 0.000 description 1
238000012360 testing method Methods 0.000 description 1
230000005026 transcription initiation Effects 0.000 description 1
230000005030 transcription termination Effects 0.000 description 1
238000000844 transformation Methods 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
229960004799 tryptophan Drugs 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
229940035893 uracil Drugs 0.000 description 1
238000010792 warming Methods 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
- C07K14/675—Beta-endorphins
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
General Health & Medical Sciences (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Zoology (AREA)
General Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Microbiology (AREA)
Wood Science & Technology (AREA)
Urology & Nephrology (AREA)
Biophysics (AREA)
Physics & Mathematics (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Hematology (AREA)
Crystallography & Structural Chemistry (AREA)
Analytical Chemistry (AREA)
Cell Biology (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
Plant Pathology (AREA)
Food Science & Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Investigating Or Analysing Biological Materials (AREA)
Saccharide Compounds (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

CA000427371A 1982-05-06 1983-05-04 Fabrication et expression de genes structuraux Expired - Lifetime CA1266628A (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US375,493		1982-05-06
US06/375,493 US4652639A (en)	1982-05-06	1982-05-06	Manufacture and expression of structural genes

Publications (1)

Publication Number	Publication Date
CA1266628A true CA1266628A (fr)	1990-03-13

Family

ID=23481109

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000427371A Expired - Lifetime CA1266628A (fr)	1982-05-06	1983-05-04	Fabrication et expression de genes structuraux

Country Status (8)

Country	Link
US (1)	US4652639A (fr)
EP (1)	EP0108787B1 (fr)
JP (1)	JPH0789934B2 (fr)
CA (1)	CA1266628A (fr)
DE (1)	DE3381438D1 (fr)
IL (1)	IL68491A (fr)
IT (1)	IT1212983B (fr)
WO (1)	WO1983004029A1 (fr)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6936694B1 (en)	1982-05-06	2005-08-30	Intermune, Inc.	Manufacture and expression of large structural genes
US4652639A (en) *	1982-05-06	1987-03-24	Amgen	Manufacture and expression of structural genes
US7138505B1 (en)	1984-01-12	2006-11-21	Novartis Vaccines And Diagnostics, Inc.	Factor VIII:C nucleic acid molecules
US6291662B1 (en)	1984-12-05	2001-09-18	Amgen Inc.	Recombinant methods for production of serine protease inhibitors and DNA sequences
US5871956A (en) *	1984-12-06	1999-02-16	Amgen Inc.	Recombinant methods for production of serine inhibitors and DNA sequences useful for same
US5900400A (en) *	1984-12-06	1999-05-04	Amgen Inc.	Serine protease inhibitor analogs
US6132990A (en) *	1984-12-06	2000-10-17	Amgen Boulder Inc.	Recombinant methods for production of serine protease inhibitors and DNA sequences useful for same
US6018030A (en)	1986-11-04	2000-01-25	Protein Polymer Technologies, Inc.	Peptides comprising repetitive units of amino acids and DNA sequences encoding the same
US4835260A (en) *	1987-03-20	1989-05-30	Genetics Institute, Inc.	Erythropoietin composition
WO1989009780A1 (fr) *	1988-04-15	1989-10-19	Chemical Industry Institute Of Toxicology	Oligodesoxynucleotides marques au tritium specifiques a un site
US5594113A (en) *	1988-06-23	1997-01-14	Associates Of Cape Cod, Inc.	Endotoxin binding and neutralizing protein and uses thereof
US6043057A (en) *	1988-09-16	2000-03-28	Vitec Aktiebolag	Recombinant systems for expression of the cholera B-sub-unit with the aid of foreign promoters and/or leader peptides
US5268276A (en) *	1988-09-16	1993-12-07	Jan Holmgren	Recombinant systems for expression of cholera B-sub-unit with the aid of foreign promoters and/or leader peptides
ATE123303T1 (de) *	1988-10-13	1995-06-15	Fujisawa Pharmaceutical Co	D-aminosäureoxidase.
US5766939A (en) *	1989-05-05	1998-06-16	Baylor College Of Medicine	Production of recombinant lactoferrin and lactoferrin polypeptides using CDNA sequences in various organisms
US6100054A (en) *	1989-05-05	2000-08-08	Baylor College Of Medicine	Production for recombinant lactoferrin and lactoferrin polypeptides using DNA sequences in various organisms
IL94183A (en)	1989-05-05	2003-09-17	Baylor College Medicine	cDNA SEQUENCE CODING FOR HUMAN LACTOFERRIN PROTEIN OR PORTION THEREOF AND LACTOFERRIN PROTEIN PRODUCED FROM SAID SEQUENCE
US5571697A (en) *	1989-05-05	1996-11-05	Baylor College Of Medicine Texas Medical Center	Expression of processed recombinant lactoferrin and lactoferrin polypeptide fragments from a fusion product in Aspergillus
US5571691A (en) *	1989-05-05	1996-11-05	Baylor College Of Medicine	Production of recombinant lactoferrin and lactoferrin polypeptides using CDNA sequences in various organisms
US5849881A (en) *	1989-05-05	1998-12-15	Baylor College Medicine	Production of recombinant lactoferrin and lactoferrin polypeptides using cDNA sequences in various organisms
US5807828A (en) *	1989-06-16	1998-09-15	Cor Therapeutics, Inc.	Platelet aggregation inhibitors
JP2527035B2 (ja) *	1989-06-16	1996-08-21	東洋紡績株式会社	クレアチニン・アミドヒドロラ―ゼをコ―ドする遺伝子を含有するｄｎａ断片、該ｄｎａ断片を有する組換えベクタ―及び該組換えベクタ―を有する形質転換体、並びにクレアチニン・アミドヒドロラ―ゼの製造方法
US5318899A (en) *	1989-06-16	1994-06-07	Cor Therapeutics, Inc.	Platelet aggregation inhibitors
US5686570A (en) *	1989-06-16	1997-11-11	Cor Therapeutics, Inc.	Platelet aggregation inhibitors
US5627262A (en) *	1989-07-05	1997-05-06	The Board Of Regents Of The University Of Oklahoma	Method and composition for the treatment of septic shock
IL95495A (en) *	1989-08-29	1996-10-16	Hoechst Ag	Fusion proteins their preparation and use
US5358857A (en) *	1989-08-29	1994-10-25	The General Hospital Corp.	Method of preparing fusion proteins
US5227293A (en) *	1989-08-29	1993-07-13	The General Hospital Corporation	Fusion proteins, their preparation and use
DK16490D0 (da) *	1990-01-19	1990-01-19	Novo Nordisk As	Enzym
IL97311A0 (en) *	1990-02-23	1992-05-25	Lilly Co Eli	Vectors and compounds for expression of glycosylation mutants of human protein c
US5322785A (en) *	1990-04-26	1994-06-21	New England Biolabs, Inc.	Purified thermostable DNA polymerase obtainable from thermococcus litoralis
US5756334A (en) *	1990-04-26	1998-05-26	New England Biolabs, Inc.	Thermostable DNA polymerase from 9°N-7 and methods for producing the same
US5500363A (en) *	1990-04-26	1996-03-19	New England Biolabs, Inc.	Recombinant thermostable DNA polymerase from archaebacteria
US5352778A (en) *	1990-04-26	1994-10-04	New England Biolabs, Inc.	Recombinant thermostable DNA polymerase from archaebacteria
US5670350A (en) *	1990-08-20	1997-09-23	Novartis Finance Corporation	Genomic DNA encoding a pseudomonas global transcriptional activation element and its use in activating gene expression
US5244796A (en) *	1990-10-12	1993-09-14	Syracuse University	Cloned leuconostoc mesenteroides glucose-6-phosphate dehydrogenase genes and method of making glucose-6-phospate dehydrogenase
JP4236698B2 (ja) *	1990-11-26	2009-03-11	ジェネティックスインスティチュート，リミテッドライアビリティカンパニー	宿主細胞でのｐａｃｅの発現およびその使用法
JP3483880B2 (ja) *	1991-04-02	2004-01-06	ノボザイムスアクティーゼルスカブ	キシラナーゼ、これに対応する組み換えｄｎａ配列、キシラナーゼ含有剤、及びこの剤の使用
US5876985A (en) *	1991-04-25	1999-03-02	Board Of Regents, The University Of Texas System	Methods and compositions for the preparation of recombinant Trichomonas vaginalis proteins and peptides
DE4117747A1 (de) *	1991-05-30	1992-12-03	Bayer Ag	Kaffeoyl-coa 3-o-methyltransferase-gene
DE4208277A1 (de) *	1992-03-13	1993-09-16	Bosch Gmbh Robert	Verkehrsrundfunkempfaenger
DK42092D0 (fr) *	1992-03-27	1992-03-27	Novo Nordisk As
US6174666B1 (en)	1992-03-27	2001-01-16	The United States Of America As Represented By The Department Of Health And Human Services	Method of eliminating inhibitory/instability regions from mRNA
ZA932568B (en) *	1992-04-24	1993-11-12	Baylor College Midecine A Non	Production of recombinant human lactoferrin
US5621089A (en) *	1992-05-27	1997-04-15	Novo Nordisk Biotech, Inc.	Nucleic acid constructs for the production of a Bacillus alkaline protease
US6869925B1 (en) *	1992-09-09	2005-03-22	Amgen Inc.	Inhibition of retrovirus infection
US7008783B1 (en)	1992-09-22	2006-03-07	Maruha Corporation	Gene encoding chondroitinase ABC and uses therefor
US5776755A (en) *	1992-10-09	1998-07-07	Helsinki University Licensing, Ltd.	FLT4, a receptor tyrosine kinase
US6107046A (en) *	1992-10-09	2000-08-22	Orion Corporation	Antibodies to Flt4, a receptor tyrosine kinase and uses thereof
US6824777B1 (en) *	1992-10-09	2004-11-30	Licentia Ltd.	Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
US5484727A (en) *	1992-10-14	1996-01-16	Trustees Of Dartmouth College	Cloned gene encoding acylcoenzyme A: cholesterol acyltransferase (ACAT)
JPH08503852A (ja) *	1992-11-25	1996-04-30	ユニバーシティオブピッツバーグオブザコモンウェルスシステムオブハイヤーエデュケーション	ヒト誘導性一酸化窒素シンターゼのｃＤＮＡクローンおよびその作製方法
US5712366A (en) *	1993-05-25	1998-01-27	The United States Of America As Represented By The Secretary Of The Army	Fabrication of nanoscale materials using self-assembling proteins
DK72593D0 (da) *	1993-06-18	1993-06-18	Symbicom Ab	Rekombinant protein
US5804558A (en) *	1993-07-20	1998-09-08	University Of California	Protegrins
US6159936A (en) *	1993-07-20	2000-12-12	The Regents Of The University Of California	Compositions and methods for treating and preventing microbial and viral infections
US5693486A (en) *	1993-07-20	1997-12-02	Intrabiotics	DNA sequences encoding protegrins and protegrin analogs and their use in recombinant methods of producing protegrins
US6653442B1 (en)	1993-07-20	2003-11-25	Intrabiotics Pharmaceuticals, Inc.	Protegrins
US5616485A (en) *	1993-12-23	1997-04-01	Cangene Corporation	Streptomyces proteases and improved streptomyces strains for expression of peptides and polypeptides
US6001604A (en) *	1993-12-29	1999-12-14	Bio-Technology General Corp.	Refolding of proinsulins without addition of reducing agents
US6017880A (en) *	1994-03-09	2000-01-25	Amgen Inc.	Inhibition of retrovirus infection
JP3198842B2 (ja) *	1994-03-24	2001-08-13	トヨタ自動車株式会社	ゲラニルゲラニル二リン酸合成酵素およびそれをコードするｄｎａ
US5786464C1 (en) *	1994-09-19	2012-04-24	Gen Hospital Corp	Overexpression of mammalian and viral proteins
US5795737A (en) *	1994-09-19	1998-08-18	The General Hospital Corporation	High level expression of proteins
US5741898A (en) *	1994-09-22	1998-04-21	Hanley; Kathleen Marie	DNA sequence encoding nicotiana squalene synthetase
JP2938352B2 (ja) *	1994-09-30	1999-08-23	オリエンタル酵母工業株式会社	組換え人マトリライシンの製造方法
EP1353952B1 (fr)	1994-11-14	2007-04-11	Ludwig Institute For Cancer Research	Flt4 (vegfr-3) utilise comme cible pour l'imagerie des tumeurs et le traitement antitumoral
IT1275909B1 (it) *	1995-03-07	1997-10-24	Mirella Pilone	Frammento di dna codificante d-amminoacido ossidasi
US5646025A (en) *	1995-05-05	1997-07-08	Novo Nordisk A/S	Scytalidium catalase gene
US6025326A (en) *	1995-07-07	2000-02-15	Intrabiotics Pharmaceuticals, Inc.	Compositions and methods for the prevention and treatment of oral mucositis
JP3709422B2 (ja) *	1995-07-21	2005-10-26	昌清水	ニトリラーゼ遺伝子発現に関わる調節因子およびその遺伝子
WO1997014787A1 (fr) *	1995-10-18	1997-04-24	Novartis Ag	Sequences nucleotidiques codant pour la mevalonate pyrophosphate decarboxylase
US5994306A (en) *	1995-11-22	1999-11-30	Intrabiotics Pharmaceuticals, Inc.	Fine-tuned protegrins
US6111081A (en) *	1996-05-31	2000-08-29	Baylor College Of Medicine	Lactoferrin variants and uses thereof
US5916872A (en) *	1996-07-24	1999-06-29	Intrabiotics Pharmaceuticals, Inc.	Cyclic peptides having broad spectrum antimicrobial activity
US6114148C1 (en) *	1996-09-20	2012-05-01	Gen Hospital Corp	High level expression of proteins
US6110668A (en) *	1996-10-07	2000-08-29	Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V.	Gene synthesis method
PT1538206E (pt) *	1997-09-16	2010-04-12	Centocor Ortho Biotech Inc	Método para a síntese química e construção completa de genes e genomas
US6670127B2 (en)	1997-09-16	2003-12-30	Egea Biosciences, Inc.	Method for assembly of a polynucleotide encoding a target polypeptide
AU774266B2 (en) *	1998-10-09	2004-06-24	Vegenics Limited	Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
AU2487300A (en) *	1998-12-31	2000-07-31	Chiron Corporation	Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
ES2299276T3 (es)	1998-12-31	2008-05-16	Novartis Vaccines And Diagnostics, Inc.	Polipeptidos env del vih modificados.
WO2000039302A2 (fr)	1998-12-31	2000-07-06	Chiron Corporation	Expression amelioree de polypeptides hiv et production de particules de type viral
US7935805B1 (en)	1998-12-31	2011-05-03	Novartis Vaccines & Diagnostics, Inc	Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
US6107460A (en) *	1999-03-01	2000-08-22	The Board Of Regents Of The University Of Oklahoma	Antimicrobial peptides and methods of use thereof
US8137906B2 (en) *	1999-06-07	2012-03-20	Sloning Biotechnology Gmbh	Method for the synthesis of DNA fragments
AU2001275091A1 (en)	2000-06-02	2001-12-17	Blue Heron Biotechnology, Inc.	Methods for improving the sequence fidelity of synthetic double-stranded oligonucleotides
US20040241650A1 (en) *	2001-01-19	2004-12-02	Evans Glen A	Computer-directed assembly of a polynucleotide encoding a target polypeptide
US7164992B1 (en)	2001-03-22	2007-01-16	Blue Heron Biotechnology, Inc.	Method and system for polynucleotide synthesis
CA2458995C (fr) *	2001-08-31	2013-04-30	Chiron Corporation	Polynucleotides codant des polypeptides de type b du vih antigeniques, polypeptides et leurs utilisations
ATE414767T1 (de) *	2001-11-22	2008-12-15	Sloning Biotechnology Gmbh	Nukleinsäure-linker und deren verwendung in der gensynthese
CN102660564B (zh)	2004-04-22	2013-05-08	泰勒克里斯生物治疗学公司	重组修饰的纤溶酶
PL2220221T3 (pl) *	2007-11-29	2015-07-31	Grifols Therapeutics Inc	Rekombinacyjnie zmodyfikowana plazmina
US9115352B2 (en)	2008-03-31	2015-08-25	Sloning Biotechnology Gmbh	Method for the preparation of a nucleic acid library
MX2010013282A (es) *	2008-06-04	2010-12-21	Talecris Biotherapeutics Inc	Composicion, metodo y kit para la preparacion de plasmina.
HUE025670T2 (en)	2009-03-03	2016-04-28	Grifols Therapeutics Inc	A method for producing plasminogen
KR101808751B1 (ko)	2009-11-13	2017-12-13	그리폴스 테라퓨틱스 인코포레이티드	폰 빌레브란트 인자(ｖＷＦ)-함유 제제, 및 그와 관련된 방법, 키트 및 용도
WO2011150168A1 (fr)	2010-05-28	2011-12-01	Gen9, Inc.	Procédés et dispositifs de synthèse in situ d'acides nucléiques
DE102010056289A1 (de)	2010-12-24	2012-06-28	Geneart Ag	Verfahren zur Herstellung von Leseraster-korrekten Fragment-Bibliotheken
US12595500B2 (en)	2011-09-26	2026-04-07	Life Technologies Corporation	High efficiency, small volume nucleic acid synthesis
CN103945931B (zh)	2011-09-26	2017-03-22	基因技术股份公司	高效的小体积核酸合成
WO2014153188A2 (fr)	2013-03-14	2014-09-25	Life Technologies Corporation	Synthèse hautement efficace de petits volumes d'acides nucléiques
WO2013093760A2 (fr)	2011-12-19	2013-06-27	Grifols, S.A.	Compositions, procédés et trousses pour la préparation de protéines recombinantes sialylées
WO2013130487A2 (fr)	2012-02-29	2013-09-06	Duke University	Nouvelles oxydoréductases pour réactions énantiosélectives
US10407676B2 (en)	2014-12-09	2019-09-10	Life Technologies Corporation	High efficiency, small volume nucleic acid synthesis
EP3763818A1 (fr)	2015-10-06	2021-01-13	Pierce Biotechnology, Inc.	Dispositifs et procédés de production de protéines
WO2024132094A1 (fr)	2022-12-19	2024-06-27	Thermo Fisher Scientific Geneart Gmbh	Extraction de molécules d'acide nucléique à séquence vérifiée

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4225784A (en) *	1976-06-17	1980-09-30	Smith Kline Instruments, Inc.	Covalently bound biological substances to plastic materials and use in radioassay
US4140662A (en) *	1977-03-25	1979-02-20	Ortho Diagnostics, Inc.	Attachment of proteins to inert particles
US4366246A (en) *	1977-11-08	1982-12-28	Genentech, Inc.	Method for microbial polypeptide expression
US4322499A (en) *	1978-12-22	1982-03-30	The Regents Of The University Of California	Adrenocorticotropin-lipotropin precursor gene
US4293652A (en) *	1979-05-25	1981-10-06	Cetus Corporation	Method for synthesizing DNA sequentially
US4342832A (en) *	1979-07-05	1982-08-03	Genentech, Inc.	Method of constructing a replicable cloning vehicle having quasi-synthetic genes
US4350764A (en) *	1980-03-10	1982-09-21	The Regents Of The University Of California	Microbiological synthesis of beta endorphin
IE53166B1 (en) *	1980-08-05	1988-08-03	Searle & Co	Synthetic urogastrone gene,corresponding plasmid recombinants,transformed cells,production thereof and urogastrone expression
US4403036A (en) *	1980-12-02	1983-09-06	University Of Iowa Research Foundation	Genetic reagents for generating plasmids containing multiple copies of DNA segments
US6936694B1 (en) *	1982-05-06	2005-08-30	Intermune, Inc.	Manufacture and expression of large structural genes
WO1983004030A1 (fr) *	1982-05-06	1983-11-24	Applied Molecular Genetics, Inc.	Fabrication et expression de genes pour l'urogastrone et leurs analogues polypeptides
US4652639A (en) *	1982-05-06	1987-03-24	Amgen	Manufacture and expression of structural genes
WO1983004028A1 (fr) *	1982-05-06	1983-11-24	Applied Molecular Genetics, Inc.	Fabrication et expression de genes pour la calcitonine et ses analogues de polypeptide

1982
- 1982-05-06 US US06/375,493 patent/US4652639A/en not_active Expired - Lifetime
1983
- 1983-04-15 EP EP83901773A patent/EP0108787B1/fr not_active Expired - Lifetime
- 1983-04-15 DE DE8383901773T patent/DE3381438D1/de not_active Expired - Lifetime
- 1983-04-15 WO PCT/US1983/000563 patent/WO1983004029A1/fr not_active Ceased
- 1983-04-15 JP JP58501807A patent/JPH0789934B2/ja not_active Expired - Lifetime
- 1983-04-26 IL IL68491A patent/IL68491A/xx not_active IP Right Cessation
- 1983-05-04 CA CA000427371A patent/CA1266628A/fr not_active Expired - Lifetime
- 1983-05-04 IT IT8367481A patent/IT1212983B/it active

Also Published As

Publication number	Publication date
IT1212983B (it)	1989-12-07
EP0108787A4 (fr)	1986-11-07
IL68491A (en)	1990-07-26
EP0108787A1 (fr)	1984-05-23
WO1983004029A1 (fr)	1983-11-24
IL68491A0 (en)	1983-07-31
JPS59501096A (ja)	1984-06-28
JPH0789934B2 (ja)	1995-10-04
DE3381438D1 (de)	1990-05-17
EP0108787B1 (fr)	1990-04-11
IT8367481A0 (it)	1983-05-04
US4652639A (en)	1987-03-24

Legal Events

Date	Code	Title	Description
2007-03-13	MKEX	Expiry

Publication	Publication Date	Title
CA1266628A (fr)	1990-03-13	Fabrication et expression de genes structuraux
EP0108128B1 (fr)	1991-12-18	(Met-1,des-Cys1,des-Tyr2,des-Cys3) interféron gamma humain et séquence d'ADN qui le code
CA1340872C (fr)	2000-01-11	Expression microbienne de l'interleukine ii
EP0095350A2 (fr)	1983-11-30	Un procédé pour la préparation d'un polypeptide semblable au gamma interféron humain
GB2162851A (en)	1986-02-12	beta -urogastrone gene
WO1983004028A1 (fr)	1983-11-24	Fabrication et expression de genes pour la calcitonine et ses analogues de polypeptide
EP0163603B1 (fr)	1989-12-13	Facteur humain de croissance de cellule-T
JPH0712312B2 (ja)	1995-02-15	改良された抗生物質耐性遺伝子
AU583018B2 (en)	1989-04-20	Gibbon interleukin
JPS59501095A (ja)	1984-06-28	カルシトニンおよびその類似体のための遺伝子の製造と発現